Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

被引：1
|
作者：
Venditti, Adriano [1 ]
Hou, Jing-Zhou [2 ]
Fenaux, Pierre [3 ]
Jonas, Brian A. [4 ]
Vrhovac, Radovan [5 ,6 ]
Montesinos, Pau [7 ]
Garcia, Jacqueline S. [8 ]
Rizzieri, David [9 ]
Thirman, Michael J. [10 ]
Kotey, Stanley [11 ]
Potluri, Jalaja [11 ]
Dhalla, Mazaher [11 ]
Pullarkat, Vinod [12 ]
机构：
[1] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy
[2] UPMC Hillman Canc Ctr, Lemieux Ctr Blood Canc, Hematol & BMT, Pittsburgh, PA USA
[3] Univ Paris, St Louis Hosp, Dept Hematol, Paris, France
[4] Univ Calif Davis, Div Malignant Hematol Cellular Therapy & Transpla, Dept Internal Med, Sch Med, Sacramento, CA USA
[5] Univ Hosp Ctr Zagreb, Dept Haematol, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Zagreb, Croatia
[7] Hosp Univ & Politecn La Fe, Valencia, Spain
[8] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[9] Novant Hlth Canc Inst, Winston Salem, NC USA
[10] Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL USA
[11] AbbVie Inc, N Chicago, IL USA
[12] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
    Choi, Eun-Ji
    Lee, Je-Hwan
    Park, Han-Seung
    Lee, Jung-Hee
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Woo, Ji Min
    Lee, Kyoo-Hyung
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : 290 - +
  • [42] Decitabine Versus Intensive Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
    Choi, Eun-Ji
    Lee, Je-Hwan
    Park, Han-Seung
    Lee, Jung-Hee
    Seol, Miee
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Woo, Ji Min
    Lee, Kyoo Hyung
    BLOOD, 2018, 132
  • [43] Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy
    Pabst, Thomas
    Vey, Norbert
    Ades, Lionel
    Bacher, Ulrike
    Bargetzi, Mario
    Fung, Samson
    Gaidano, Gianluca
    Gandini, Domenica
    Hultberg, Anna
    Johnson, Amy
    Ma, Xuewen
    Muller, Rouven
    Nottage, Kerri
    Papayannidis, Cristina
    Recher, Christian
    Riether, Carsten
    Shah, Priya
    Tryon, Jeffrey
    Xiu, Liang
    Ochsenbein, Adrian F.
    HAEMATOLOGICA, 2023, 108 (07) : 1793 - 1802
  • [44] Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy
    Choi, Michelle
    Song, Jinlin
    Bui, Cat N.
    Ma, Esprit
    Chai, Xinglei
    Yin, Lei
    Betts, Keith A.
    Kapustyan, Tatyana
    Montez, Melissa
    LeBlanc, Thomas William
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (09): : 980 - 988
  • [45] Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7+3 Type Chemotherapy or Venetoclax/Azacitidine
    Islam, Nazmul
    Reuben, Jamie S.
    Dale, Justin
    Gutman, Jon
    McMahon, Christine M.
    Amaya, Maria
    Goodman, Bruce
    Toninato, Joseph
    Gasparetto, Maura
    Stevens, Brett
    Pei, Shanshan
    Gillen, Austin
    Staggs, Sarah
    Engel, Krysta
    Davis, Sarah
    Hull, Madelyne
    Burke, Elizabeth
    Larchick, Lenny
    Zane, Richard
    Weller, Grant
    Jordan, Craig
    Smith, Clay
    JCO CLINICAL CANCER INFORMATICS, 2022, 6 : e2200030
  • [46] Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Laille, Eric
    Gong, Jing
    Prebet, Thomas
    De Menezes, Daniel Lopes
    Wei, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
    Ramdohr, Florian
    Hennings, Robert
    Monecke, Astrid
    Kayser, Sabine
    HAEMATOLOGICA, 2023, 108 (07) : 1965 - 1967
  • [48] A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
    Fathi, Amir T.
    Fell, Geoffrey G.
    El-Jawahri, Areej
    Perl, Alexander E.
    Jonas, Brian A.
    Dias, Ajoy L.
    Mims, Alice S.
    Borate, Uma
    Ragon, Brittany Knick
    Grunwald, Michael R.
    Peters, Mary Linton B.
    Graubert, Timothy A.
    Amrein, Philip C.
    Hock, Hanno R.
    Brunner, Andrew M.
    Hobbs, Gabriela S.
    Narayan, Rupa
    Neuberg, Donna S.
    Aldoss, Ibrahim
    BLOOD, 2022, 140 : 3284 - 3286
  • [49] Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine.
    De Botton, Stephane
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Riva, Marta
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Hui, Jianan
    Gianolio, Diego A.
    Patel, Prapti Arvind
    Recher, Christian
    Dohner, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Updated efficacy and safety data from the AGILE study in patients with newly-diagnosed acute myeloid leukemia treated with ivosidenib plus azacitidine compared to placebo plus azacitidine
    Heuser, M.
    Montesinos, P.
    Vives, Polo S.
    Zarzycka, E.
    Wang, J.
    Riva, M.
    Calado, R. T.
    Schuh, A. C.
    Yeh, S. -P
    Hui, J.
    Gianolio, D. A.
    Patel, P.
    Recher, C.
    de Botton, S.
    Doehner, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 95 - 95
12345